Skip to main content
. 2021 Apr 6;13(7):1733. doi: 10.3390/cancers13071733

Figure 6.

Figure 6

Variation of plasmatic levels of hsa-miR-186-3p according to clinicopathological characteristics (mean ± SE); (A) healthy individuals vs. ccRCC patients; (B) clinical stage I + II vs. clinical stage III + IV; (C) Fuhrman grade G1-G2 vs. Fuhrman grade G3-G4; (D) no recurrence vs. recurrence.